{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:10:27Z","timestamp":1793171427682,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR) Research for Patient Benefit","award":["NIHR205348"],"award-info":[{"award-number":["NIHR205348"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the association between fragility fracture and interruption of bisphosphonate prescription after three and five years of initial prescription, and to explore the incidence of atypical femoral fracture and osteonecrosis of jaw after three and five years of continued prescription of bisphosphonates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nested case-control and cohort studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Clinical Practice Research Datalink Aurum, an anonymised longitudinal database of NHS primary care electronic health records, linked to hospital admission and mortality records from Hospital Episode Statistics and Office for National Statistics databases, respectively, 1 January 1997 to 31 December 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults aged \u226518 years on the date of the first prescription of alendronate or risedronate, and with primary care data linked to Hospital Episode Statistics and Office for National Statistics databases. Participants with a medication possession ratio of \u226567% in each of the first three and five years were followed up from the three or five year time points to the earliest of fragility fracture, death, end of study, two years, or last data availability. Cases were those who had a fragility fracture and were matched with up to four control participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Incidence of fragility fracture, atypical femoral fracture, and osteonecrosis of jaw were main outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data for 26 809 and 13 408 participants prescribed bisphosphonates for three and five years, respectively, were included. Fragility fracture was not associated with interruption of bisphosphonate prescription or intermittent prescription compared with continuous prescription in those previously prescribed bisphosphonates for three years (adjusted odds ratio 1.02, 95% confidence interval (CI) 0.85 to 1.24 and 1.13, 0.93 to 1.38, respectively) or five years (adjusted odds ratio 0.92, 0.75 to 1.13 and 0.87, 0.67 to 1.13, respectively). Time since last prescription was not associated with fragility fracture. After three and five years of bisphosphonate prescription, the incidence of atypical femoral fractures was 1.93 (95% CI 1.55 to 2.41) and 2.50 (1.92 to 3.26) per 1000 person years, respectively, and the incidence of osteonecrosis of jaw was 0.07 (0.02 to 0.21) and 0.00 per 1000 person years, respectively, within two years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription. The incidence of atypical femoral fracture or osteonecrosis of jaw was uncommon and rare respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-002085","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:25:24Z","timestamp":1776864324000},"page":"e002085","source":"Crossref","is-referenced-by-count":2,"title":["Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies"],"prefix":"10.1136","volume":"5","author":[{"given":"Georgina","family":"Nakafero","sequence":"first","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"McKeever","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-0028","authenticated-orcid":false,"given":"Niraj S","family":"Kukreja","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Welsh","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University, Newcastle-under-Lyme, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-5751","authenticated-orcid":false,"given":"Sara","family":"Muller","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Newcastle-under-Lyme, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026042208301770000_5.1.e002085.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927"},{"key":"2026042208301770000_5.1.e002085.2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1494"},{"key":"2026042208301770000_5.1.e002085.3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.11"},{"key":"2026042208301770000_5.1.e002085.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525"},{"key":"2026042208301770000_5.1.e002085.5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00198-024-07262-7","article-title":"Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink","volume":"36","author":"Persson","year":"2025","journal-title":"Osteoporos Int"},{"key":"2026042208301770000_5.1.e002085.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1202619"},{"key":"2026042208301770000_5.1.e002085.7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708."},{"key":"2026042208301770000_5.1.e002085.8","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"key":"2026042208301770000_5.1.e002085.9","unstructured":"National Osteoporosis Guideline Group U . Clinical guideline for the prevention and treatment of osteoporosis: NOGG; 2044. Available: https:\/\/www.nogg.org.uk\/full-guideline [Accessed 4 Jul 2025]."},{"key":"2026042208301770000_5.1.e002085.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0460-7"},{"key":"2026042208301770000_5.1.e002085.11","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040326"},{"key":"2026042208301770000_5.1.e002085.12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","article-title":"Fracture risk following intermission of osteoporosis therapy","volume":"30","author":"Dennison","year":"2019","journal-title":"Osteoporos Int"},{"key":"2026042208301770000_5.1.e002085.13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026042208301770000_5.1.e002085.14","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S164112"},{"key":"2026042208301770000_5.1.e002085.15","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1013"},{"key":"2026042208301770000_5.1.e002085.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128232","article-title":"Opioids contribute to fracture risk: a meta-analysis of 8 cohort studies","volume":"10","author":"Zhu Y,","year":"2015","journal-title":"PLoS One"},{"key":"2026042208301770000_5.1.e002085.17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00198-022-06376-0","article-title":"Prevalence of osteoporosis in osteoarthritis: a systematic review and meta-analysis","volume":"33","author":"Kim","year":"2022","journal-title":"Osteoporos Int"},{"key":"2026042208301770000_5.1.e002085.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/28.5.964"},{"key":"2026042208301770000_5.1.e002085.19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1536867X0800800103","article-title":"A Tool for Deterministic and Probabilistic Sensitivity Analysis of Epidemiologic Studies","volume":"8","author":"Orsini","year":"2008","journal-title":"The Stata Journal: Promoting Communications on Statistics and Stata"},{"key":"2026042208301770000_5.1.e002085.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21554"},{"key":"2026042208301770000_5.1.e002085.21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026042208301770000_5.1.e002085.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25190","article-title":"Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women","volume":"3","author":"Izano","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026042208301770000_5.1.e002085.23","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001294"},{"key":"2026042208301770000_5.1.e002085.24","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"key":"2026042208301770000_5.1.e002085.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"key":"2026042208301770000_5.1.e002085.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116297"},{"key":"2026042208301770000_5.1.e002085.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4132-y"},{"key":"2026042208301770000_5.1.e002085.28","doi-asserted-by":"crossref","unstructured":"Kim SH , Lee Y-K , Kim T-Y , et al . Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study. Bone 2021;143. doi:10.1016\/j.bone.2020.115650","DOI":"10.1016\/j.bone.2020.115650"},{"key":"2026042208301770000_5.1.e002085.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2042-6"},{"key":"2026042208301770000_5.1.e002085.30","doi-asserted-by":"crossref","first-page":"105599","DOI":"10.1016\/j.jbspin.2023.105599","article-title":"Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database","volume":"90","author":"Amigues","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2026042208301770000_5.1.e002085.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2011.09.001"},{"key":"2026042208301770000_5.1.e002085.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.190"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-002085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:30:27Z","timestamp":1776871827000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-002085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjmed-2025-002085"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-002085","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}